Company news

Context Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

January 3, 2023

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

December 7, 2022

Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers

December 5, 2022

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

November 28, 2022

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

November 20, 2022

Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results

November 8, 2022

Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024

September 26, 2022

Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results

August 10, 2022

Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination

August 1, 2022

Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results

May 10, 2022

Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting

May 4, 2022

Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

April 10, 2022

Context Therapeutics® Reports Full Year 2021 Operating and Financial Results

March 22, 2022

Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022

March 7, 2022

Context Therapeutics® Strengthens Research & Development Team

January 4, 2022

Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium

December 8, 2021

Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement

December 5, 2021

Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results

December 1, 2021

Context Therapeutics Inc. Announces $31.25 Million Private Placement

November 30, 2021

Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer

October 31, 2021

Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer

October 26, 2021

Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option

October 21, 2021

← Newer news releases

Decks

The 5 newest of 25 decks. Every deck is listed under its year.